Skip to main content

News Center

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

2024

2023

2022

November 24, 2022 
The impact of inaction - New publication reveals not all of Canada is on track to meet global hepatitis C elimination goal

November 16, 2022 
Canadian migraine sufferers have new treatment option - Health Canada approves UBRELVY® (ubrogepant tablet)

October 20, 2022
AbbVie’s SKYRIZI® (risankizumab) receives Health Canada approval as the first and only specific Interleukin-23 (IL-23) to treat moderately to severely active Crohn’s Disease in adults

October 13, 2022
For World Sight Day, new app available for Canadians living with glaucoma, the Silent Thief of Sight

September 27, 2022 
XEN® 63 Gel Implant available now for patients with primary open angle glaucoma where previous medical treatments have failed

July 20, 2022 
Health Canada approves AbbVie’s RINVOQ® (upadacitinib) for the treatment of adults with active ankylosing spondylitis

June 22, 2022 
MAVIRET® (glecaprevir/pibrentasvir) approved by Health Canada for pediatric patients with chronic hepatitis C

April 27, 2022 
Health Canada approves VRAYLAR® (cariprazine) for the treatment of bipolar l disorder and schizophrenia in adults 

March 17, 2022
AbbVie expands immunology portfolio in Canada as Health Canada approves SKYRIZI® (risankizumab) for the treatment of adults with active psoriatic arthritis

March 9, 2022 
Focusing on the silent thief of sight during World Glaucoma Week

February 15, 2022 
AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology patients
 

2021

2020

2019

December 18, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

December 6, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis

October 23, 2019
AbbVie’s Suzanne Campbell recognized by peers

September 25, 2019
VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada

July 25, 2019
AbbVie is committed to the elimination of hepatitis C in Canada by 2030

June 6, 2019
AbbVie Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia

May 30, 2019
AbbVie’s MAVIRET™ now listed in New Brunswick

May 23, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)

May 21, 2019
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

April 18, 2019
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

April 11, 2019
AbbVie’s MAVIRET™ now reimbursed in Quebec

February 21, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™

February 20, 2019
AbbVie’s HUMIRA® (Adalimumab) approved by Health Canada to treat pediatric patients with chronic non-infectious anterior
 

2018

2017